secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001125345-24-000065
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Phase 2 TAMARACK safety data shows improved tolerability at lower vobra duo doses
--------------------------------------------------------------------------------

- Drug interruption rate 12.6% vs 58.5% at 12 weeks in Phase 1; discontinuation 5.3% vs 14.6%.
- No fatal AEs; most common TEAEs: asthenia (40.7%), nausea (27.7%), fatigue (20.3%).
- ASCO abstract not accepted; plan to share updated interim safety + efficacy by May 31, 2024.
- rPFS primary endpoint data expected Fall 2024; IDMC recommended study continue unchanged.
- Enrolled 182 mCRPC patients across 2.0 and 2.7 mg/kg Q4W dose arms; 85.7% still on treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000065/0001125345-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000065/mgnx-20240403.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer